EMA of­fers method­olog­i­cal con­sid­er­a­tions for tri­als dur­ing Covid-19 pan­dem­ic

The Eu­ro­pean Med­i­cines Agency (EMA) on Wednes­day re­leased for con­sul­ta­tion a new draft guide­line on points that clin­i­cal tri­al spon­sors should con­sid­er on the im­pli­ca­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER